<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>PubTator</source><date>2020-12-04</date><key>BioC.key</key>
<document><id>28068936</id><passage><infon key="type">title</infon><offset>0</offset><text>Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.</text><annotation id="0"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="23" length="3"/><text>RAS</text></annotation><annotation id="1"><infon key="NCBI Gene identifier">5290</infon><infon key="type">STARGENE</infon><location offset="27" length="6"/><text>PIK3CA</text></annotation><annotation id="2"><infon key="NCBI Gene identifier">673</infon><infon key="type">STARGENE</infon><location offset="34" length="4"/><text>BRAF</text></annotation></passage><passage><infon key="type">abstract</infon><offset>167</offset><text>BACKGROUND: After analysis of minor RAS mutations (KRAS exon 3, 4/NRAS) in the FIRE-3 and PRIME studies, an expanded range of RAS mutations were established as a negative predictive marker for the efficacy of anti-EGFR antibody treatment. BRAF and PIK3CA mutations may be candidate biomarkers for anti-EGFR targeted therapies. However, it remains unknown whether RAS/PIK3CA/BRAF tumor mutations can predict the efficacy of bevacizumab in metastatic colorectal cancer. We assessed whether selection according to RAS/PIK3CA/BRAF mutational status could be beneficial for patients treated with bevacizumab as first-line treatment for metastatic colorectal cancer. METHODS: Of the 1001 consecutive colorectal cancer patients examined for RAS, PIK3CA, and BRAF tumor mutations using a multiplex kit (LuminexÂ®), we studied 90 patients who received combination chemotherapy with bevacizumab as first-line treatment for metastatic colorectal cancer. The objective response rate (ORR) and progression-free survival (PFS) were evaluated according to mutational status. RESULTS: The ORR was higher among patients with wild-type tumors (64.3%) compared to those with tumors that were only wild type with respect to KRAS exon 2 (54.8%), and the differences in ORR between patients with wild-type and mutant-type tumors were greater when considering only KRAS exon 2 mutations (6.8%) rather than RAS/PIK3CA/BRAF mutations (18.4%). There were no statistically significant differences in ORR or PFS between all wild-type tumors and tumors carrying any of the mutations. Multivariate analysis revealed that liver metastasis and RAS and BRAF mutations were independent negative factors for disease progression after first-line treatment with bevacizumab. CONCLUSIONS: Patient selection according to RAS/PIK3CA/BRAF mutations could help select patients who will achieve a better response to bevacizumab treatment. We found no clinical benefit of restricting combination therapy with bevacizumab for metastatic colorectal cancer patients with EGFR-wild type tumors.</text><annotation id="3"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="203" length="3"/><text>RAS</text></annotation><annotation id="4"><infon key="NCBI Gene identifier">3845</infon><infon key="type">STARGENE</infon><location offset="218" length="4"/><text>KRAS</text></annotation><annotation id="5"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="233" length="4"/><text>NRAS</text></annotation><annotation id="6"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="293" length="3"/><text>RAS</text></annotation><annotation id="7"><infon key="NCBI Gene identifier">1956</infon><infon key="type">Gene</infon><location offset="381" length="4"/><text>EGFR</text></annotation><annotation id="8"><infon key="NCBI Gene identifier">673</infon><infon key="type">STARGENE</infon><location offset="406" length="4"/><text>BRAF</text></annotation><annotation id="9"><infon key="NCBI Gene identifier">5290</infon><infon key="type">STARGENE</infon><location offset="415" length="6"/><text>PIK3CA</text></annotation><annotation id="10"><infon key="NCBI Gene identifier">1956</infon><infon key="type">Gene</infon><location offset="469" length="4"/><text>EGFR</text></annotation><annotation id="11"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="530" length="3"/><text>RAS</text></annotation><annotation id="12"><infon key="NCBI Gene identifier">5290</infon><infon key="type">STARGENE</infon><location offset="534" length="6"/><text>PIK3CA</text></annotation><annotation id="13"><infon key="NCBI Gene identifier">673</infon><infon key="type">STARGENE</infon><location offset="541" length="4"/><text>BRAF</text></annotation><annotation id="14"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="678" length="3"/><text>RAS</text></annotation><annotation id="15"><infon key="NCBI Gene identifier">5290</infon><infon key="type">STARGENE</infon><location offset="682" length="6"/><text>PIK3CA</text></annotation><annotation id="16"><infon key="NCBI Gene identifier">673</infon><infon key="type">STARGENE</infon><location offset="689" length="4"/><text>BRAF</text></annotation><annotation id="17"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="901" length="3"/><text>RAS</text></annotation><annotation id="18"><infon key="NCBI Gene identifier">5290</infon><infon key="type">STARGENE</infon><location offset="906" length="6"/><text>PIK3CA</text></annotation><annotation id="19"><infon key="NCBI Gene identifier">673</infon><infon key="type">STARGENE</infon><location offset="918" length="4"/><text>BRAF</text></annotation><annotation id="20"><infon key="NCBI Gene identifier">3845</infon><infon key="type">STARGENE</infon><location offset="1370" length="4"/><text>KRAS</text></annotation><annotation id="21"><infon key="NCBI Gene identifier">3845</infon><infon key="type">STARGENE</infon><location offset="1508" length="4"/><text>KRAS</text></annotation><annotation id="22"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="1549" length="3"/><text>RAS</text></annotation><annotation id="23"><infon key="NCBI Gene identifier">5290</infon><infon key="type">STARGENE</infon><location offset="1553" length="6"/><text>PIK3CA</text></annotation><annotation id="24"><infon key="NCBI Gene identifier">673</infon><infon key="type">STARGENE</infon><location offset="1560" length="4"/><text>BRAF</text></annotation><annotation id="25"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="1778" length="3"/><text>RAS</text></annotation><annotation id="26"><infon key="NCBI Gene identifier">673</infon><infon key="type">STARGENE</infon><location offset="1786" length="4"/><text>BRAF</text></annotation><annotation id="27"><infon key="NCBI Gene identifier">4893</infon><infon key="type">STARGENE</infon><location offset="1948" length="3"/><text>RAS</text></annotation><annotation id="28"><infon key="NCBI Gene identifier">5290</infon><infon key="type">STARGENE</infon><location offset="1952" length="6"/><text>PIK3CA</text></annotation><annotation id="29"><infon key="NCBI Gene identifier">673</infon><infon key="type">STARGENE</infon><location offset="1959" length="4"/><text>BRAF</text></annotation><annotation id="30"><infon key="NCBI Gene identifier">1956</infon><infon key="type">Gene</infon><location offset="2190" length="4"/><text>EGFR</text></annotation></passage></document>
</collection>
